The PPARα–leukotriene B4 pathway to inflammation control
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Inflammation is a local immune response to 'foreign' molecules, infection and injury. Leukotriene B4, a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response, is shown to be an activating ligand for the transcription factor PPARalpha. Because PPARalpha regulates the oxidative degradation of fatty acids and their derivatives, like this lipid mediator, a feedback mechanism is proposed that controls the duration of an inflammatory response and the clearance of leukotriene B4 in the liver. Thus PPARalpha offers a new route to the development of anti- or pro-inflammatory reagents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FFAs act as PPAR agonists facilitating translocation to the nucleus and dimerization to RXR [77,78].”
From Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation (2021) · cites this paper as [77]
In the citing paper
“PPAR-α is involved in the regulation of pro-inflammatory genes, mainly by limiting cytokine expression.[109]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [109]
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Self-citationKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
Self-citationKliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Self-citation
Research works printed but not linked: 6
- Ford-Hutchinson, A. W. Crit. Rev. Immunol. 10, 1–11 (1990).
- Desvergne, B. & Wahli, W. in Inducible Transcription Vol. 1 (ed. Bæuerle, P.) 142–176 (Birkhäuser, Boston, 1995).
- Greene, M. E. et al. Gene Expr. 4, 281–299 (1995).
- Schmidt, A. et al. Mol. Endocrinol. 6, 1634–1641 (1992).
- Yu, K. et al. J. Biol. Chem. 270, 23975–23983 (1995). · DOI · Paper page
- Peters, J. M. et al. Mol. Pharmacol. 50, 67–94 (1996).
Cited by
Items 501–600 of 1,001
Keller, J. M., Collet, P., Bianchi, A., Huin‐Schohn, C., Krémarik, P., Bécuwe, P., Schohn, H., Domenjoud, L., & Dauça, M. (2000) · The International Journal of Developmental Biology · doi:10.1387/ijdb.11032176 · Cited by 82
“Some arachidonic acid metabolites such as the leukotriene B4 (LTB4) and the prostaglandin J2 (PGJ2) derivative, 15 deoxy∆12,14 PGJ2, represent natural ligands for PPARα (Devchand et al., 1996) and PPARγ (Forman et al.”
InfluentialPeroxisome Proliferator-Activated Receptors and Skin Development
Rosenfield, R. L., Deplewski, D., & Greene, M. E. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053270 · Cited by 69
Zileuton, a new efficient and safe systemic anti-acne drug
Zouboulis, C. C. (2009) · Dermato-Endocrinology · doi:10.4161/derm.1.3.8368 · Cited by 70
Autophagy-activating strategies to promote innate defense against mycobacteria
Kim, Y. S., Silwal, P., Kim, S. Y., Yoshimori, T., & Jo, E. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0290-7 · Cited by 76
Chou, W.-C., & Lin, Z. (2020) · Environment International · doi:10.1016/j.envint.2020.105581 · Cited by 68
Pawliczak, R., Han, C. L., Huang, X., DEMETRIS, A., Shelhamer, J. H., & Wu, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200246200 · Cited by 75
Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer
Wagner, N., & Wagner, K. (2022) · Cells · doi:10.3390/cells11152432 · Cited by 73
The role of the LTB 4 -BLT1 axis in chemotactic gradient sensing and directed leukocyte migration
Subramanian, B. C., Majumdar, R., & Parent, C. A. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.002 · Cited by 68
PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma
Banno, A., Reddy, A. T., Lakshmi, S. P., & Reddy, R. C. (2018) · Nuclear Receptor Research · doi:10.11131/2018/101306 · Cited by 72
“PPARα was first shown to control the duration of inflammatory responses in a mouse earswelling model [31].”
Mechanisms of Peroxisome Proliferation by Perfluorooctanoic Acid and Endogenous Fatty Acids
Intrasuksri, U., Rangwala, S. M., O'Brien, O., Noonan, D. J., & Feller, D. R. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00029-9 · Cited by 68
PPAR-alpha in cutaneous inflammation
Dubrac, S., & Schmuth, M. (2011) · Dermato-Endocrinology · doi:10.4161/derm.3.1.14615 · Cited by 66
Regulation of Peroxisome Proliferator-Activated Receptors
Sørensen, H. N., Treuter, E., & Gustafsson, J.-Å. (1998) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60924-3 · Cited by 74
Inhibition of lipoxygenase by soy isoflavones: Evidence of isoflavones as redox inhibitors
Gangadhariah, M. H., Singh, S. A., & Rao, A. G. A. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.02.013 · Cited by 67
Morgenweck, J., Abdel‐Aleem, O. S., McNamara, K. C., Donahue, R. R., Badr, M. Z., & Taylor, B. K. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.10.008 · Cited by 74
“For example, systemic administration of PPARa or PPARg ligands reduce peripheral inflammation in vivo (Cuzzocrea et al., 2004; Oliveira et al., 2007; Taylor et al., 2002), in part by acting at PPARs located in liver or at the site of inflammation (Devchand et al., 1996; Napimoga et al., 2008).”
BackgroundA Lipid Gate for the Peripheral Control of Pain
Piomelli, D., Hohmann, A. G., Seybold, V. S., & Hammock, B. D. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3475-14.2014 · Cited by 71
“…-null animals are insensitive to the antinociceptive effects of PPAR- agonists but are hypersensitive to various proalgesic and proinflammatory stimuli (Devchand et al., 1996; Ruiz-Medina et al., 2012), which is suggestive of a role for PPAR- in the tonic control of nociception and inflammation.”
BackgroundCernuda‐Morollón, E., Rodríguez‐Pascual, F., Klatt, P., Lamas, S., & Pérez‐Sala, D. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000025786.87646.b1 · Cited by 71
Cloning and Function of Rabbit Peroxisome Proliferator-activated Receptor δ/β in Mature Osteoclasts
Mano, H., Kimura, C., Fujisawa, Y., Kameda, T., Mikiko, W.-M., Kaneko, H., Kaneda, T., Hakeda, Y., & Kumegawa, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8126 · Cited by 67
Janabi, N. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4747 · Cited by 67
Zhao, Y., Gul, Y., Su, L., & Wang, W. (2011) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2011.06.024 · Cited by 67
Pizzimenti, S., Laurora, S., Briatore, F., Ferretti, C., Dianzani, M. U., & Barrera, G. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00798-5 · Cited by 72
MODULATION OF DRUG METABOLISM IN INFECTIOUS AND INFLAMMATORY DISEASES*
Iber, H., Sewer, M. B., Barclay, T. B., Mitchell, S. R., Li, T., & Morgan, E. T. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101906 · Cited by 71
Zileuton, an Oral 5-Lipoxygenase Inhibitor, Directly Reduces Sebum Production
Zouboulis, C. C., Saborowski, A., & Boschnakow, A. (2005) · Dermatology · doi:10.1159/000081481 · Cited by 68
“Interestingly, the 5-lipoxygenase product leukotriene B4 is a natural ligand for PPAR-α [”
BackgroundMeier, C. A., Chicheportiche, R., Juge-Aubry, C. E., Dreyer, M. G., & Dayer, J. (2002) · Cytokine · doi:10.1006/cyto.2002.1945 · Cited by 71
Clockaerts, S., Bastiaansen-Jenniskens, Y. M., Feijt, C., Verhaar, J. A. N., Somville, J., De Clerck, L. S., & Van Osch, G. J. V. M. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.03.010 · Cited by 65
THUILLIER, P., BRASH, A. R., KEHRER, J. P., STIMMEL, J. B., LEESNITZER, L. M., YANG, P., NEWMAN, R. A., & FISCHER, S. M. (2002) · Biochemical Journal · doi:10.1042/bj20020377 · Cited by 66
Nwankwo, J. O., & Robbins, M. E. C. (2001) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0266 · Cited by 65
Howroyd, P., Swanson, C., Dunn, C., Cattley, R. C., & Corton, J. C. (2004) · Toxicologic Pathology · doi:10.1080/01926230490515283 · Cited by 65
“PPARα also indirectly controls the levels of inflammatory lipid mediators such as LTB4 and its precursor arachidonic acid catabolized through the β-oxidation pathway (Devchand et al., 1996).”
BackgroundLeukotriene B4mediates histamine induction of NF-κB and IL-8 in human bronchial epithelial cells
Aoki, Y., Qiu, D., Zhao, G. H., & Kao, P. N. (1998) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1998.274.6.l1030 · Cited by 65
Rapid pain modulation with nuclear receptor ligands
Fehrenbacher, J. C., LoVerme, J., Clarke, W. P., Hargreaves, K., Piomelli, D., & Taylor, B. K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.019 · Cited by 70
Patho-genetics of Clostridium chauvoei
Frey, J., & Falquet, L. (2014) · Research in Microbiology · doi:10.1016/j.resmic.2014.10.013 · Cited by 81
Relationship between PPARα activation and NO on proximal tubular Na+ transport in the rat
Newaz, M. A., Ranganna, K., & Oyekan, A. (2004) · BMC Pharmacology · doi:10.1186/1471-2210-4-1 · Cited by 64
“Peroxisome Proliferator Activated Receptors (PPARs) constitute a subfamily of the nuclear receptor super-family which are activated by natural ligands such as fatty aids and eicosanoids [ 12-14 ].”
BackgroundZiouzenkova, O., Asatryan, L., Sahady, D., Orasanu, G., Perrey, S., Cutak, B., Hassell, T., Akiyama, T. E., Berger, J. P., Sevanian, A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306786200 · Cited by 64
Hazzan, R., & Tur-Kaspa, R. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c115b3 · Cited by 64
Activation of nuclear receptors by prostaglandins
Ide, T., Egan, K. M., Bell, L. C., & FitzGerald, G. A. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00418-3 · Cited by 70
Valmaseda, A., Carmona, M. C., Barberà, M. J., Viñas, O., Mampel, T., Iglesias, R., Villarroya, F., & Giralt, M. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00081-7 · Cited by 70
Mansouri, R. M., Baugé, E., Staels, B., & Gervois, P. (2008) · Endocrinology · doi:10.1210/en.2007-1339 · Cited by 61
Perfluorooctanoic acid alters T lymphocyte phenotypes and cytokine expression in mice
Son, H., Lee, S., Tak, E., Cho, H., Shin, H., Kim, S., & Yang, J. (2009) · Environmental Toxicology · doi:10.1002/tox.20459 · Cited by 62
“Inflammation is a local immune response to infection and injury (Devchand et al., 1996).”
BackgroundEberhardt, W., Akool, E., Rebhan, J. ̈., Frank, S., Beck, K., Franzen, R., Hamada, F. M. A., & Pfeilschifter, J. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202008200 · Cited by 63
HAN, X. F., WANG, Q. X., LIU, Y., YOU, Z. R., BIAN, Z. L., QIU, D. K., & MA, X. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2012.00574.x · Cited by 63
Sasso, O., Russo, R., Vitiello, S., Raso, G. M., D’Agostino, G., Iacono, A., La Rana, G., Vallée, M., Cuzzocrea, S., Piazza, P. V., et al. (2012) · Pain · doi:10.1016/j.pain.2011.08.010 · Cited by 62
Pinto, C., Rodrigues, P., Rocha, E. M., & Lobo‐da‐Cunha, A. (2005) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2005.09.001 · Cited by 74
Eicosanoids: Atherosclerosis and cardiometabolic health
Piper, K., & Garelnabi, M. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100216 · Cited by 74
Discrete Role for Cytosolic Phospholipase A2α in Platelets
Wong, D. A., Kita, Y., Uozumi, N., & Shimizu, T. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011443 · Cited by 62
“There is mounting evidence for the dual role, an intracellular role and an intercellular/extracellular role, for any given lipid mediator (42).”
Gong, L., Wei, F., Gonzalez, F. J., & Li, G. (2023) · Hepatology · doi:10.1097/hep.0000000000000182 · Cited by 71
Self-citationYeh, C., Chen, T.-P., Lee, C.-H., Wu, Y., Lin, Y., & Lin, P. J. (2006) · Shock · doi:10.1097/01.shk.0000225863.56714.96 · Cited by 61
Grabacka, M., Pierzchalska, M., & Reiss, K. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201011314030009 · Cited by 58
Roy, N. C., Barnett, M. P. G., Knoch, B., Dommels, Y. E. M., & McNabb, W. C. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.04.003 · Cited by 72
Insights into the Role of PPARβ/δ in NAFLD
Chen, J., Montagner, A., Tan, N. S., & Wahli, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071893 · Cited by 55
Self-citationChinetti, G., Fruchart, J., & Staels, B. (2001) · Zeitschrift für Kardiologie · doi:10.1007/s003920170034 · Cited by 68
Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection
Yoshikai, Y. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200106000-00003 · Cited by 72
Novel Role of Oxidants in the Molecular Mechanism of Action of Peroxisome Proliferators
Rusyn, I., Rose, M., Bojes, H. K., & Thurman, R. G. (2000) · Antioxidants and Redox Signaling · doi:10.1089/15230860050192350 · Cited by 61
“However, this adaptive response to perturbations in lipid metabolism cannot be differentiated from the PPAR pathway, since fatty acids and products of their metabolism are also ligands for PPARa (Devchand et al., 1996; Kliewer et al., 1997).”
Mastyugin, V., Aversa, E., Bonazzi, A., Vafaes, C., Mieyal, P. A., & Schwartzman, M. L. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38312-0 · Cited by 61
Molecular defects in genetic diseases of peroxisomes
Fujiki, Y. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00051-3 · Cited by 67
Edvardsson, U., Alexandersson, M., von Löwenhielm, H. B., Nyström, A., Ljung, B., Nilsson, F. Y., & Dahllöf, B. (1999) · Electrophoresis · doi:10.1002/(sici)1522-2683(19990101)20:4/5<935::aid-elps935>3.0.co;2-6 · Cited by 62
PPARs as Key Mediators in the Regulation of Metabolism and Inflammation
Vázquez‐Carrera, M., & Wahli, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095025 · Cited by 60
Self-citationLipids as targets for novel anti-inflammatory therapies
Huwiler, A., & Pfeilschifter, J. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.008 · Cited by 74
Gyamfi, M. A., He, L., French, S. W., Damjanov, I., & Wan, Y. Y. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132258 · Cited by 61
“Our results demonstrating the important role of RXR in inflammation is also supported by findings that PPAR -deficient mice had prolonged inflammatory response after arachidonic acid or leukotriene B4 administration (Devchand et al., 1996).”
Planagumà, A., Titos, E., López‐Parra, M., Gaya, J., Pueyo, G., Arroyo, V., & Clària, J. (2002) · The FASEB Journal · doi:10.1096/fj.02-0224fje · Cited by 59
Still, K., Grabowski, P., Mackie, I. P., Perry, M., & Bishop, N. J. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9175-9 · Cited by 60
“PPARa plays an important role in lipid metabolism by regulating the genes involved in fatty acid oxidation and has some anti-inflammatory activity [ 2 , 3]. PPARd has been implicated in several processes, including oligodendrocyte differentiation, cholesterol transport, wound healing, and placental development [4].”
BackgroundEffect of Topical PPARβ/δ and PPARγ Agonists on Plaque Psoriasis
Kuenzli, S., & Saurat, J.-H. (2003) · Dermatology · doi:10.1159/000068897 · Cited by 59
Chen, X., Zhang, Y., & Funk, C. D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31237 · Cited by 65
PPARγ: observations in the hematopoietic system☆
Greene, M. E., Pitts, J. M., McCarville, M. B., Wang, X.-S., Newport, J. A., Edelstein, C. L., Lee, F., Ghosh, S., & Chu, S. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00075-7 · Cited by 61
Protection of dopaminergic neurons by 5-lipoxygenase inhibitor
Kang, K., Liou, H.-H., Hour, M., Liou, H., & Fu, W. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.014 · Cited by 59
“Leukotrienes are biologically active molecules that may convey messages by interactingwith specificmembrane G-protein coupled receptors (Yokomizo et al., 1997) and likely regulate transcription by binding an intranuclear orphan receptor (Devchand et al., 1996).”
BackgroundHydroxyeicosapentaenoic acids from the Pacific krill show high ligand activities for PPARs
Yamada, H., Oshiro, E., Kikuchi, S., Hakozaki, M., Takahashi, H., & Kimura, K. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m047514 · Cited by 61
Han, C. L., Demetris, A. J., Liu, Y., Shelhamer, J. H., & Wu, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404852200 · Cited by 64
RetractedGaudreau, R., Gouill, C. L., Venne, M.-H., Staňková, J., & Rola‐Pleszczynski, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202723200 · Cited by 58
Arck, P., Tóth, B., Pestka, A., & Jeschke, U. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.110.083550 · Cited by 62
Bisgaier, C. L., Essenburg, A. D., Barnett, B. C., Auerbach, B. J., Haubenwallner, S., Leff, T., White, A. D., Creger, P., Pape, M. E., Rea, T. J., et al. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34199-7 · Cited by 58
Pregnane X Receptor Modulates the Inflammatory Response in Primary Cultures of Hepatocytes
Sun, M., Cui, W., Woody, S. K., & Staudinger, J. L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062307 · Cited by 61
Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages
Andersson, C., Zaman, M. M., Jones, A. B., & Freedman, S. D. (2007) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2007.05.004 · Cited by 60
Esposito, E., Rinaldi, B., Mazzon, E., Donniacuo, M., Impellizzeri, D., Paterniti, I., Capuano, A., Bramanti, P., & Cuzzocrea, S. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-81 · Cited by 58
The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
Devchand, P. R., Liu, T., Altman, R. B., FitzGerald, G. A., & Schadt, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01093 · Cited by 54
“…of sVCAM-1 expression was delineated using the PPARα-deficient mouse (Orasanu et al., 2008), a seminal animal model on the involvement of PPARs in xenobiotic responsiveness (e.g., Lee et al., 1995) and on the progression of a successful inflammatory defense (e.g., Devchand et al., 1996).”
MethodSelf-citationIs There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?
Tufano, M., & Pinna, G. (2020) · Molecules · doi:10.3390/molecules25051062 · Cited by 59
“MPTP MDG548 PPAR-γ Mediate neuroprotection in microglia; promote anti-inflammatory cytokines [59]”
BackgroundTNF-α inhibits PPARβ/δ activity and SIRT1 expression through NF-κB in human adipocytes
Serrano, L., Chacón, M. R., Maymó‐Masip, E., Barroso, E., Salvadó, L., Wabitsch, M., Garrido‐Sánchez, L., Tinahones, F. J., Palomer, X., Vendrell, J. J., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.05.006 · Cited by 68
“In addition, PPARs suppress inflammation through diversemechanisms, for example by reducing the release of inflammatory factors or stabilizing repressive complexes at inflammatory gene promoters [11–14].”
BackgroundLipid metabolism and inflammation modulated by Vitamin D in liver of diabetic rats
Ning, C., Liu, L., Lv, G., Yang, Y., Zhang, Y., Yu, R., Wang, Y., & Zhu, J. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0030-5 · Cited by 63
Membrane Localization and Topology of Leukotriene C4 Synthase
Christmas, P., Weber, B. M., McKee, M. L., Brown, D., & Soberman, R. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203074200 · Cited by 57
Guo, C., Zhang, Y., He, L., Wang, F., Chen, K., Li, J., Li, S., Liu, T., Zheng, Y., Wang, J., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s79837 · Cited by 54
Mogilenko, D. A., Kudriavtsev, I. V., Shavva, V. S., Dizhe, E. B., Vilenskaya, E. G., Efremov, A. M., Perevozchikov, A. P., & Orlov, S. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.437525 · Cited by 52
Salunkhe, S. A., Chitkara, D., Mahato, R. I., & Mittal, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.003 · Cited by 57
Kurihara, T. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)03975-2 · Cited by 55
The anti-catabolic effects of n-3 fatty acids
Ross, J. A., Moses, A. G. W., & Fearon, K. C. H. (1999) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-199905000-00005 · Cited by 55
PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?
Balakumar, P., Rose, M., & Singh, M. (2007) · Pharmacology · doi:10.1159/000102594 · Cited by 59
Orphan Nuclear Receptors: An Emerging Family of Metabolic Regulators
SLADEK, R. M., & Giguère, V. (1999) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60109-x · Cited by 65
PPARγ Ligands Inhibit TNF-α-Induced LOX-1 Expression in Cultured Endothelial Cells
Chiba, Y., Ogita, T., Ando, K., & Fujita, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5361 · Cited by 55
PPARα as a therapeutic target in inflammation-associated diseases
Gervois, P. P., & Mansouri, R. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.715633 · Cited by 58
Sehgal, N., Kumawat, K. L., Basu, A., & Ravindranath, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035427 · Cited by 54
“through its action as PPARα agonist can enhance its metabolism, thus diminishing the inflammatory response”
BackgroundGocke, A. R., Hussain, R. Z., Yang, Y., Peng, H., Weiner, J., Ben, L.-H., Drew, P. D., Stüve, O., Lovett‐Racke, A. E., & Racke, M. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713927 · Cited by 54
Devillier, P., Baccard, N., & Advenier, C. (1999) · Pharmacological Research · doi:10.1006/phrs.1998.0458 · Cited by 65
Dzhagalov, I. L., Chambon, P., & He, Y.-W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2113 · Cited by 60
Role of PPARs in Radiation-Induced Brain Injury
Ramanan, S., Zhao, W., Riddle, D. R., & Robbins, M. E. C. (2009) · PPAR Research · doi:10.1155/2010/234975 · Cited by 55
“These findings are not surprising; PPARα KO mice exhibit a prolonged response to inflammatory stimuli such as lipopolysaccharide and leukotriene B4 [116, 117].”
Background"Anti-Inflammatory" Drugs and Their Effects on Type 2 Diabetes
Deans, K. A., & Sattar, N. A. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.18 · Cited by 56
Peroxisome Proliferator-Activated Receptor Agonists Inhibit Inflammatory Edema and Hyperalgesia
Taylor, B. K., Dadia, N., Yang, C. B., Krishnan, S., & Badr, M. Z. (2002) · Inflammation · doi:10.1023/a:1015500531113 · Cited by 53
Characterization of Multiple Enhancer Regions Upstream of the Apolipoprotein(a) Gene
Wade, D. P., Puckey, L., Knight, B. L., Acquati, F., Mihalich, A., & Taramelli, R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30387 · Cited by 60
Genovese, T., Mazzon, E., Paola, R. D., Cannavò, G., Muià, C., Bramanti, P., & Cuzzocrea, S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.03.003 · Cited by 57
Park, Y., & Pariza, M. W. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(01)00171-8 · Cited by 53
Cell biology of peroxisomes and their characteristics in aquatic organisms
Cancio, I., & Cajaraville, M. P. (2000) · International review of cytology · doi:10.1016/s0074-7696(00)99005-3 · Cited by 58
Nonalcoholic Fatty Liver Disease
Sanyal, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.014 · Cited by 53
Gijsbers, L., Man, H.-Y., Kloet, S. K., de Haan, L. H. J., Keijer, J., Rietjens, I. M. C. M., van der Burg, B., & Aarts, J. M. M. J. G. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.02.032 · Cited by 60
Greaves, P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53856-7.00009-9 · Cited by 61
Tang, H., Raney, A. K., & McLachlan, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.8937-8948.2001 · Cited by 54
Metadata
- Authors
- Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W.
- Affiliations
- University of Lausanne (CH)
- National Institutes of Health (US)
- Venue
- Nature
- Published
- 1996-11
- Volume
- 384
- Issue
- 6604
- Pages
- 39-43
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1671834350
- Cited by
- 1,345
- References
- 43
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 14 · 2023: 21 · 2022: 9 · 2021: 38 · 2020: 30 · 2019: 23 · 2018: 21 · 2017: 24 · 2016: 23 · 2015: 22 · 2014: 43 · 2013: 34 · 2012: 49
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- PPARα, leukotriene B4, inflammation, transcription factor activation, fatty acid oxidation, lipid mediators, chemotaxis, anti-inflammatory agents, liver, feedback regulation
- MeSH terms
- Adaptation, Physiological, Animals, Cells, Cultured, Fatty Acids, Female, Gene Expression Regulation, HeLa Cells, Humans, Inflammation, Leukotriene B4, Ligands, Liver, Male, Oxidation-Reduction, Plasmids, Pyrimidines, Time Factors, Transcription Factors, Transfection, Chloramphenicol O-Acetyltransferase, Arachidonic Acid, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Inflammation Mediators, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.